Allt inom Corporate Information
Notice of annual general meeting in Nanexa AB (publ)
The shareholders in Nanexa AB (publ),reg.no 556833–0285 (the ”Company”) are hereby given notice that the annual general meeting will be held on Thursday 15 May 2025, at. 3:00 pm, at Uppsala Business Park, Rapsgatan 7, Uppsala, Sweden.
Continued Good Tolerability of NEX-22 at 30 mg Dose of Liraglutide in the NEX-22 Study
Nanexa AB announces that initial observations in the phase I study show that the 30 mg dose of NEX-22, a depot formulation of liraglutide, has been well tolerated by patients with type 2 diabetes who have not previously received GLP-1 treatment.